These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9806352)

  • 21. An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.
    Demirpence E; Semlali A; Oliva J; Balaguer P; Badia E; Duchesne MJ; Nicolas JC; Pons M
    Cancer Res; 2002 Nov; 62(22):6519-28. PubMed ID: 12438246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists.
    Montano MM; Müller V; Trobaugh A; Katzenellenbogen BS
    Mol Endocrinol; 1995 Jul; 9(7):814-25. PubMed ID: 7476965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha.
    Aliau S; Mattras H; Richard E; Bonnafous JC; Borgna JL
    Biochemistry; 2002 Jun; 41(25):7979-88. PubMed ID: 12069588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of free DNA on the interactions of the estrogen receptor bound to hormone, partial antagonist or pure antagonist with target DNA.
    Aliau S; Groblewski T; Borgna JL
    Eur J Biochem; 1995 Jul; 231(1):204-13. PubMed ID: 7628472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity.
    Fan JD; Wagner BL; McDonnell DP
    Mol Endocrinol; 1996 Dec; 10(12):1605-16. PubMed ID: 8961270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro.
    Koshida S; Narita T; Kato H; Yoshida S; Taga T; Ohta S; Takeuchi Y
    Jpn J Cancer Res; 2002 Dec; 93(12):1351-7. PubMed ID: 12495475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.
    Bowers JL; Tyulmenkov VV; Jernigan SC; Klinge CM
    Endocrinology; 2000 Oct; 141(10):3657-67. PubMed ID: 11014220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
    Lyman SD; Jordan VC
    Biochem Pharmacol; 1985 Aug; 34(15):2795-806. PubMed ID: 4015716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequence requirements for estrogen receptor binding to estrogen response elements.
    Driscoll MD; Sathya G; Muyan M; Klinge CM; Hilf R; Bambara RA
    J Biol Chem; 1998 Nov; 273(45):29321-30. PubMed ID: 9792632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.
    Mobbs BG; Johnson IE; DeSombre ER; Toth J; Hughes A
    Cancer Res; 1987 May; 47(10):2645-51. PubMed ID: 3552202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma.
    Coward P; Lee D; Hull MV; Lehmann JM
    Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8880-4. PubMed ID: 11447273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction of estrogen- and antiestrogen-receptor complexes with polynucleotides.
    Murphy LC; Sutherland RL
    Endocrinology; 1983 Feb; 112(2):707-14. PubMed ID: 6848368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor-induced DNA bending: orientation of the bend and replacement of an estrogen response element with an intrinsic DNA bending sequence.
    Nardulli AM; Grobner C; Cotter D
    Mol Endocrinol; 1995 Aug; 9(8):1064-76. PubMed ID: 7476980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen-receptor--DNA interaction. Difference between activation by estrogen and antiestrogen.
    Evans E; Baskevitch PP; Rochefort H
    Eur J Biochem; 1982 Nov; 128(1):185-91. PubMed ID: 7173202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen response element binding induces alterations in estrogen receptor-alpha conformation as revealed by susceptibility to partial proteolysis.
    Ramsey TL; Klinge CM
    J Mol Endocrinol; 2001 Dec; 27(3):275-92. PubMed ID: 11719281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of tetrahydrocrysene ketone with estrogen receptors alpha and beta indicates conformational differences in the receptor subtypes.
    Tyulmenkov VV; Klinge CM
    Arch Biochem Biophys; 2000 Sep; 381(1):135-42. PubMed ID: 11019829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.